Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
10 hedge funds and large institutions have $678K invested in Evoke Pharma in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
25% more funds holding
Funds holding: 8 → 10 (+2)
2.94% more ownership
Funds ownership: 14.66% → 17.6% (+2.9%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
30% less capital invested
Capital invested by funds: $966K → $678K (-$287K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$105K |
| 2 |
BRF
B. Riley Financial
Los Angeles,
California
|
+$84.9K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$904 |
| 4 |
Morgan Stanley
New York
|
+$140 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$5.56K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$174 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NCM
1
Nantahala Capital Management
New Canaan,
Connecticut
| $407K | -$174 | -41 | -0% |
|
|
BL
2
Bleichroeder LP
New York
| $189K | – | – | – |
|
|
3
Citadel Advisors
Miami,
Florida
| $68.2K | +$105K | +24,803 | New |
|
|
BRF
4
B. Riley Financial
Los Angeles,
California
| $12.2K | +$84.9K | +20,000 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $586 | +$904 | +213 | New |
|
6
BlackRock
New York
| $336 | – | – | – |
|
|
SS
7
SBI Securities
Tokyo,
Japan
| $206 | – | – | – |
|
|
8
Morgan Stanley
New York
| $176 | +$140 | +33 | +106% |
|
|
NA
9
NewEdge Advisors
New Orleans,
Louisiana
| $47 | – | – | – |
|
10
Bank of America
Charlotte,
North Carolina
| $25 | – | – | – |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$5.56K | -1,258 | Closed |
|
EVOK Hedge Fund Activity: Q1 2025 in Review
10 of the 7,463 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q1 2025, worth a combined $678K — down 30% from $966K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new EVOK positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $105K. The largest seller was UBS Group, exiting entirely with an estimated $5.56K sold.
- 10 institutional investors held Evoke Pharma (EVOK) as of Q1 2025, up from 8 in Q4 2024.
- Funds reported $678K of Evoke Pharma stock for Q1 2025, down 30% quarter-over-quarter.
- 3 funds opened new Evoke Pharma positions in Q1 2025 and 1 closed out, a net change of +2 holders.
- The largest Evoke Pharma buyer in Q1 2025 was Citadel Advisors, an estimated $105K added.
- The largest Evoke Pharma seller in Q1 2025 was UBS Group, an estimated $5.56K sold.
Based on aggregated 13F filings for Q1 2025.